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Human noroviruses (HuNoVs) are major contributors to acute nonbacterial gastroenteritis
outbreaks. Many aspects of HuNoVs are poorly understood due to both the current
inability to culture HuNoVs, and the lack of efficient small animal models. Surrogates
for HuNoVs, such as recombinant viral like particles (VLPs) expressed in eukaryotic
system or P particles expressed in prokaryotic system, have been used for studies in
immunology and interaction between the virus and its receptors. However, it is difficult to
use VLPs or P particles to collect or isolate potential ligands binding to these recombinant
capsid proteins. In this study, a new strategy was used to collect HuNoVs binding
ligands through the use of ice nucleation protein (INP) to display recombinant capsid
proteins of HuNoVs on bacterial surfaces. The viral protein-ligand complex could be
easily separated by a low speed centrifugation step. This system was also used to
explore interaction between recombinant capsid proteins of HuNoVs and their receptors.
In this system, the VP1 capsid encoding gene (ORF2) and the protruding domain (P
domain) encoding gene (3′ terminal fragment of ORF2) of HuNoVs GI.1 and GII.4 were
fused with 5′ terminal fragment of INP encoding gene (inaQn). The results demonstrated
that the recombinant VP1 and P domains of HuNoVs were expressed and anchored
on the surface of Escherichia coli BL21 cells after the bacteria were transformed with
the corresponding plasmids. Both cell surface displayed VP1 and P domains could
be recognized by HuNoVs specific antibodies and interact with the viral histo-blood
group antigens receptors. In both cases, displayed P domains had better binding
abilities than VP1. This new strategy of using displayed HuNoVs capsid proteins on
the bacterial surface could be utilized to separate HuNoVs binding components from
complex samples, to investigate interaction between the virus and its receptors, as well
as to develop an oral vaccine for HuNoVs.
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Niu et al. Construction of Mock Human Norovirus
INTRODUCTION
Human noroviruses (HuNoVs) are one of major nonbacterial
pathogens for foodborne gastroenteritis (Atmar and Estes, 2006).
HuNoVs belong to the family of Caliciviridae. The single-
stranded, positive-sensed RNA viral genome can be divided into
three open reading frames (ORFs) (Jiang et al., 1993). The ORF2
encodes the major structural protein (VP1) which have two
domains: the shell (S) and the protruding (P) domain (Zheng
et al., 2006). The viral capsid is composed of 180 capsid protein
monomers organized into 90 dimers (Tan et al., 2008).
Due to a lack of cultivable system or animal models,
surrogate viruses such as feline calicivirus (FCV), murine
norovirus (MNV), and Tulane virus (TV) are often used
to study the fundamental biology of the viruses such as
viral replication pattern and mechanism of infection (Farkas,
2015). Recombinant human norovirus capsid proteins expressed
either by eukaryotic or prokaryotic systems are often used
for studies for immunogenicity, diagnosis assays, and host-
receptor interaction (Gray et al., 1993; Green et al., 1993;
Hutson et al., 2003; Huang et al., 2005). The virus-like particles
(VLPs), spontaneously formed in a recombinant baculovirus
system, have morphological and antigenical similarities to viral
particles (Jiang et al., 1992). However, large production of
recombinant proteins is still difficult owing to low protein yield
and lack of VLPs. Tan et al. applied E. coli expression system
to produce recombinant norovirus capsid proteins (Tan et al.,
2004). They demonstrated that the E. coli-expressed capsid
proteins maintained the same antigenicity and receptor binding
specificity as those of the baculovirus-expressed VLPs, although
the E. coli-expressed capsid proteins did not form VLPs. Tan
et al. further demonstrated that a smaller particle (P particle)
could form, which was expressed in E. coli (Tan et al., 2004).
The P particles expressed in vitro is an octahedral nanoparticle
formed by 24 copies of P monomers, most likely organized
into 12 P dimers. These P particles are easily produced in
E. coli, extremely stable, and highly immunogenic (Tan and
Jiang, 2005b). However, one disadvantage of the bacterial system
for expression of recombinant HuNoVs capsid proteins is that
the expressed capsid proteins cannot be purified easily. After
the fusion tag is removed, gel filtration and anion-exchange
chromatography are required for purification of recombinant
HuNoVs capsid proteins (Tan et al., 2004). Another disadvantage
is that VP1 and P particles expressed by bacteria are either soluble
proteins (VP1) or small particles. Therefore, it will be hard to
either collect or isolate the viral capsid protein-ligand complex.
Bacterial ice nucleation proteins (INPs) are a family of
proteins that enable Gram-negative bacteria to promote crystal
formation at relatively high temperatures (Kawahara, 2002).
Different INP coding genes from Pseudomonas syringae, Erwinia
herbicola, and Xanthomonas campestris were well characterized
(Wolber et al., 1986; Schmid et al., 1997; Jung et al., 1998a; Li
et al., 2012). INP composes three distinct structural domains: an
N-terminal domain, a C-terminal domain and a highly repetitive
central domain (Shimazu et al., 2001). So far, INPs have been
applied in various perfect bacterial cell surface display systems,
including host cells of E. coli (Jung et al., 1998b; Kwak et al.,
1999; Li et al., 2009), Salmonella typhi (Lee et al., 2000), Vibrio
anguillarum (Xu et al., 2008), P. syringae (Shimazu et al., 2003).
By transformation of bacteria with the gene encoding a fusion
target protein with the anchoringmotifs of INP, the target protein
could be directly displayed on the surface of the bacteria (Kim
and Yoo, 1999; Kwak et al., 1999; Cochet and Widehem, 2000).
It was reported that the N-terminal domain of InaQ (named
as InaQN) is responsible for the transmembrane transport and
membrane-binding activity of INP (Li et al., 2012).
In order to solve the problem of collecting ligands binding to
viral capsid proteins, recombinant HuNoVs capsid proteins were
displayed on the surface of bacteria with the help of InaQN. It
was reported that histo-blood group antigens (HBGAs) have been
recognized as receptors for HuNoVs (Hutson et al., 2003; Tan and
Jiang, 2005a). Therefore, in this study, Type III porcine gastric
mucin (PGM) containing HBGAs (Tian et al., 2008) was used
to evaluate the binding efficacy between the viral receptors and
displayed HuNoVs VP1s and P domains.
MATERIALS AND METHODS
Bacterial Strains and Plasmids
E. coli DH5α and BL21 (ThermoFisher, Shanghai, China) were
used as competent cells for recombinant plasmid construction
and protein expression. Plasmid pMD19-T (TaKaRa, Dalian,
China) inserted with different gene fragments was used for
subcloning into the prokaryotic expression plasmid pET-28a
(ThermoFisher, Shanghai, China). pCR-TORO/GI.1-ORF2+3
plasmid with inserted gene of HuNoV GI.1 ORF2 was kindly
provided by Dr. Peng Tian (PSMRU, WRRC, USDA, CA, USA).
pTrc-HisC-inaQ plasmid was kindly provided by Prof. Lin Li
(State Key Laboratory of Agricultural Microbiology, Huazhong
Agricultural University, Wuhan, China).
Cloning of inaQn, HuNoVs GI.1/GII.4 ORF2
and P Domain Coding Fragments
The coding sequence of InaQN domain (inaQn) was subcloned
from plasmid pTrc-HisC-inaQ according to the previous report
(Li et al., 2012).
HuNoV GI.1 ORF2 and its 3′ terminal fragments (named
P) were amplified from recombinant plasmid pCR-TORO/GI.1-
ORF2+3. A 1584 bp fragment for HuNoV GI.1 ORF2 (GenBank
No. M87661) and a 909 bp fragment for HuNoV GI.1 ORF2
3′ terminal were amplified by PCR. Each 20.0µL PCR reaction
including 2.0µL 10 × PCR Buffer, 1.5µL 25mmol/L Mg2+,
1 U Taq E (ThemoFisher, Shanghai, China), 1.0µL 10mmol/L
dNTPs, 1.0µL 10mmol/L of upstream and downstream primers
respectively, 2.0µL plasmid and double distilled water (dd H2O).
Thermal cycling condition consists of initial denaturation at 95◦C
for 5min, 35 cycles of template denaturation at 95◦C for 30 s,
primer annealing at 52◦C for 30 s, primer extension at 72◦C for
1min 40 s, and final extension at 72◦C for 10min.
Genomic RNA of HuNoV GII.4 strain was extracted by Trizol
Kit (ThemoFisher, Shanghai, China) from clinical gastroenteritis
samples provided by Beijing Center for Disease Control
and Prevention, China. A 1623 bp fragment (GenBank No.
Frontiers in Microbiology | www.frontiersin.org 2 December 2015 | Volume 6 | Article 1448
Niu et al. Construction of Mock Human Norovirus
TABLE 1 | Sequences of (RT-) PCR primers.
Gene fragment Primer Restriction enzyme site Sequence(5′-3′) Amplicon size (bp)
GI.1 ORF2 GI.1F Bgl II AGATCTATGATGATGGCGTCTAAGG 1584
GI.1R Hind III AAGCTTACAGACCAAGCCTACCTC
GI.1 P domain GI.1 P-F Bgl II AGATCTCAGAAAACCAGGCCCTTC 909
GI.1 P-R Hind III AAGCTTCTAAAGCCAAGCCTTACG
GII.4 ORF2 GII.4F Bgl II GGAAGATCTATGAAGATGGCGTCG 1623
GII.4R EcoR I CCGGAATTCTTATAAAGCACGTCTG
GII.4 P domain GII.4 P-F Bgl II AGATCTTCAAGAACTAAACCATTCTC 948
GII.4 P-R EcoR I GAATTCTTATAGTGCACGCCTACGCC
TABLE 2 | Recombinant plasmids with restriction enzyme sites.
Recombinant Restriction The length of nucleic
plasmids enzyme sites acid fragments (bp)
pET28a-1 Nco I & Hind III 5246
pET28a-2 Nco I & EcoR I 5265
pMD19-ORF2(GI.1) Bgl II & Hind III 1584 (GI.1 ORF2)
pMD19-ORF2(GII.4) Bgl II & EcoR I 1623 (GII.4 ORF2)
pMD19-P(GI.1) Bgl II & Hind III 909 (GI.1 P domain)
pMD19-P(GII.4) Bgl II & EcoR I 948 (GII.4 P domain)
prTc-His C-inaQ Nco I & Bgl II 525 (InaQN domain)
KM114291) for HuNoV GII.4 ORF2 was amplified by two-
step RT-PCR kit (TaKaRa, Dalian, China) in accordance with
manufacturer’s protocol. The 3′ terminal fragment (948 bp) of
ORF2 was amplified according to previous reports (Wang et al.,
2008).
All primers used in this study were listed in Table 1. PCR
products were analyzed by electrophoresis on 1.5% agarose
gels and target bands were recycled using AxyPrep DNA
gel extraction kit (Corning, Shanghai, China). The recovered
nucleic acid fragments were inserted into plasmid pMD19-
T, named pMD19-ORF2(GI.1), pMD19-ORF2(GII.4), pMD19-
P(GI.1), and pMD19-P(GII.4), respectively. The recombinant
plasmids were sequenced by Shanghai Majorbio Bio-pharm
Technology Co., Ltd.
After restriction enzymes digestion (Table 2), inaQn fragment
and ORF2 or ORF2 3′ terminal fragments from GI.1 or GII.4
were inserted into pET-28a to create recombinant plasmids
pET28a-inaQn-ORF2(GI.1), pET28a-inaQn-ORF2(GII.4),
pET28a-inaQn-P(GI.1), and pET28a-inaQn-P(GII.4),
respectively. In addition, pET28a-ORF2(GI.1), pET28a-
ORF2(GII.4), pET28a-P(GI.1), and pET28a-P(GII.4) without
the inaQn gene were also constructed as negative controls.
All recombinant plasmids were confirmed by sequencing by
Shanghai Majorbio Bio-pharm Technology Co., Ltd.
Expression of Recombinant Plasmids
Recombinant E. coli BL21 strains were transformed with different
recombinant plasmids, including pET28a-inaQn-ORF2(GI.1),
pET28a-inaQn-ORF2(GII.4), pET28a-inaQn-P(GI.1), and
pET28a-inaQn-P(GII.4), then cultured in Luria-Bertani (LB)
(0.5% yeast extract, 1% trypton, and 1% NaCl) liquid medium
containing 100µg/mL kanamycin with shaking (150 rpm) at
37◦C overnight. The transformed BL21 cells (50µL) were
transferred to 5mL fresh LB medium (100µg/mL kanamycin)
with shaking (150 rpm) at 37◦C. When the culture reached to
optical density in 600 nm (OD600) of around 0.6, 0.4mmol/L
(final concentration) isopropyl β-D-1-thiogalactopyranoside
(IPTG) was added and the cells were incubated at 16◦C for
24 h with shaking (120 rpm). The cells were kept at 4◦C for
further use.
Preparation of Antibodies for VP1 of
HuNoVs GI.1 and GII.4
Expression of Recombinant Capsid Proteins in E. coli
E. coli BL21 with recombinant plasmids pET28a-ORF2
(GI.1) and pET28a-ORF2 (GII.4) were grown in LB medium
with 100µg/mL kanamycin with shaking (150 rpm) at 37◦C
overnight. The next day, the cells (2mL) were subcultured in
fresh LB (200mL) with 100µg/mL kanamycin with shaking
(150 rpm) at 37◦C. The recombinant plasmids were expressed in
E. coli BL21 at 37◦C for 4 h after induction by 0.4mmol/L IPTG.
All induced cells were collected for further use.
Purification of Recombinant Protein and Preparation
of Specific Antibodies
Recombinant capsid protein was purified according to previous
report with minor modifications (Wang et al., 2008). Briefly, the
cells expressing viral capsid proteins at the condition described
in Section Expression of Recombinant Capsid Proteins in E.
coli were washed 3 times using PBS (pH 7.2, NaCl 137mmol/L,
KCl 2.7mmol/L, Na2HPO4 10mmol/L, KH2PO4 2mmol/L). The
cells were resuspended in 20mL Buffer A [pH 8.0, 50mmol/L
Tris-HCl, 1mmol/L EDTA, 50mmol/L NaCl, 5% glycerin (v/v),
0.5% Triton X-100 (v/v)] with 100µg/mL lysozyme (Sigma, St.
Louis, USA). After incubation at 37◦C for 30min, cells were
subjected to ultrasonic treatment (BILON92-II, Shanghai, China)
under the condition of 6 s with 4 s interval for 90 cycles on the
ice. Then cell lysate was centrifuged at 10,000 × g for 15min
at 4◦C. The precipitate (crude inclusion body) was washed by
10mL Buffer A. Twentymilliliters lysis buffer (pH 9.0, 50mmol/L
Tris-HCl, 1mmol/L EDTA, 50mmol/L NaCl, 5% glycerin (v/v),
0.5% Triton X-100 (v/v), and 8 mol/L urea) was added to
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resuspend the precipitate and then resolved slowly on the ice
for 2 h. After centrifugation at 10,000 × g at 4◦C for 30min,
the supernatant was dialyzed in TE buffer (pH 8.0, 10mmol/L
Tris-HCl, 1mmol/L EDTA) at 4◦C for 12 h. The TE buffer was
then replaced and continued second dialysis. After dialysis, the
supernatant was centrifuged at 10,000× g at 4◦C for 30min. The
recombinant protein in supernatant was analyzed by SDS-PAGE
according to our previous report (Wang et al., 2008).
Preparation of Primary Antibody Against VP1
Ten female Balb/c mice (Hubei Provincial Center for Disease
Control and Prevention, China), 5–6 weeks old, were immunized
subcutaneously with 0.1mg recombinant VP1 of HuNoV GI.1
or GII.4 every 2 weeks respectively. The sera were collected and
used as primary antibodies against the recombinant viral capsid
proteins (VP1 and P particles) after 3 months of immunization.
The sera were stored at−80◦C for further use.
Ethics Statement
All animal studies were carried out in strict accordance with the
recommendations in the Guide for the Institutional Animal Care
and Use Committee. The protocol was approved by Laboratory
Animal Feeding Standard Operation Procedure (SOP-Ani-019-
2012), the Institutional Animal Care and Use Committee, and
the Laboratory Animal Center of Shanghai Jiao Tong University
(Permit Number: A2015020).
Whole Cell Enzyme Immunoassay (EIA)
A modified sandwich EIA was developed to evaluate the
recombinant VP1 or P domains display efficiency on the surface
of host cells with or without InaQN. Briefly, the transformed
cells with recombinant plasmids pET28a-ORF2 (GI.1),
pET28a-ORF2 (GII.4), pET28a-P (GI.1), pET28a-P (GII.4)
and pET28a-inaQn-ORF2(GI.1), pET28a-inaQn-P(GI.1),
pET28a-inaQn-ORF2(GII.4), pET28a-inaQn-P(GII.4), and
plasmid pET28a as control were collected after induction of viral
protein expression as described in previous Section Expression of
Recombinant Plasmids by centrifugation at 5000 × g for 5min.
The pellet was washed with PBS (pH 7.2) twice and adjusted
OD600 to around 1.0 in 500µL PBS in a 1.5mL Eppendorf
tube. After centrifugation at 5000 × g for 5min, the pellet
was resuspended with 500µL primary antibodies against VP1
obtained from Section Preparation of Primary Antibody Against
VP1 (1:10,000 diluted in Tris-Buffered Saline and Tween-20 with
1% bovine serum albumin) and incubated for 30min at 37◦C.
After washing with Tris-Buffered Saline and Tween-20 (TBST)
for three times, the bacterial pellet was resuspended with 500µL
Peroxidase-Conjugated Goat Anti-Mouse IgG (H+L) (Yeasen,
Shanghai, China) at a dilution of 1:5000 and incubated for
30min at 37◦C. After three washes with TBST, the bacterial pellet
was resuspended in 500µL PBS. Finally, a 50µL of suspension
was taken and mixed with 50µL 3,3′,5,5′-tetramethylbenzidine
[Friendbio Science and Technology (Wuhan) Co., Ltd., Hubei,
China]. After keeping in the dark for 10min, 50µL of mixture
was transferred to 96 well module (Lantian Biological Equipment
Factory, Jiangsu, China), and 50µL 2 mol/L H2SO4 was added
to stop the reaction. OD450 value was measured using a Sunrise
Microplate Reader (Tecan Sunrise, Switzerland). In addition,
bacteria transformed with recombinant plasmids without inaQn
gene including pET28a-ORF2 (GI.1), pET28a-ORF2 (GII.4),
pET28a-P (GI.1), and pET28a-P (GII.4) were also tested.
Measuring the HBGAs Binding Abilities
Type III PGM purchased from Sigma (St, Louis, MI, USA)
was used as viral receptor. Each well of the Nunc Immuno
Module (VWR, CA, USA) was coated with 100µL of PGM
(1mg/mL in 0.05mol/L carbonate-bicarbonate buffer, pH 9.6) at
4◦C overnight. After being washed with PBS (pH 7.2) for 3 times,
the wells were blocked with 120µL of 1% bovine serum albumin
(BSA) in PBS at 37◦C for 1 h. The wells were washed with PBS
(pH 7.2) for 3 times and used immediately.
The transformed bacteria were cultured as described
in Section Expression of Recombinant Plasmids. The cells
with recombinant plasmids pET28a-inaQn-ORF2(GI.1),
pET28a-inaQn-P(GI.1), pET28a-inaQn-ORF2(GII.4), pET28a-
inaQn-P(GII.4) were collected by centrifugation at 3000 × g for
5min and diluted to 102 or 103 CFU/mL in PBS. The diluted
cells (100µL per well) were added into 48 wells, half of which
were coated with PGM, and the remainder was not coated with
PGM. After incubation at 37◦C for 30min, 10µL suspension
from each well was taken onto the LB agar plate containing
100µg/mL kanamycin for overnight at 37◦C. After incubation,
the colonies were counted. In addition, recombinant plasmids
without inaQn gene were constructed as a control including
pET28a-ORF2 (GI.1), pET28a-ORF2 (GII.4), pET28a-P (GI.1),
and pET28a-P (GII.4). The binding ratio was calculated by
comparing the difference of colony forming units (CFU) before
and after binding with or without PGM.
Binding ratio = n/N × 100%
n = (CFU in well without PGM)
−(CFU in well with PGM)
N = CFU in well without PGM
Statistical Analysis
IBM SPSS Statistics Software (version 19) was used for analyzing
statistics. Each experiment was repeated at least three times
(N = 3) as independent replicates in triplicates within each
experiment (n = 3). One-way ANOVA was utilized for data
analysis. Differences in means were considered significant when
the p < 0.05.
RESULTS
The Fusion Viral Proteins Expressed on the
Surface of Transformed Cells
A modified sandwich EIA was developed to evaluate the
recombinant VP1 or P domains display efficiency on the
surface of host cells with or without InaQN (Figure 1). The
results indicated the fusion protein could display on the surface
of bacterial cells and maintain the antigenicity of HuNoVs
(Figure 1). The absorbance was significantly higher in bacteria
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FIGURE 1 | Absorbance of 450nm (OD450) in whole cell EIA assay. The
whole cell EIA results of recombinant HuNoVs VP1/P domains () and
recombinant InaQN-HuNoVs VP1/P domains ( ). Bars represent standard
error.
transformed with plasmids of inaQn gene fused with ORF2 or
P domain coding gene than that of plasmids of ORF2 or P
domain coding gene without inaQn gene (p < 0.01). The P/N
(Positive result/Negative result) ratio of pET28a-inaQn-ORF2
(GI.1), pET28a-inaQn-P (GI.1), pET28a-inaQn-ORF2 (GII.4),
and pET28a-inaQn-P (GII.4) were 9.45, 8.93, 6.53, and 8.98
respectively. Without the inaQn, the P/N ratio of pET28a-
ORF2 (GI.1), pET28a-P (GI.1), pET28a-ORF2 (GII.4), and
pET28a-P (GII.4) were 3.81, 4.25, 2.55, and 2.77 respectively.
The presence of inaQn gene significantly increased display of
HuNoVs capsid proteins on the surface of the transformed
bacterial cells. There was no significant difference in signals
of displayed VP1 and P domains of GI.1 transformed bacteria
(p > 0.05). However, the signals of displayed P domains were
significantly higher than VP1 in GII.4 transformed bacteria
(p < 0.01). No significant difference was found among pET28a-
inaQn-ORF2 (GI.1) (OD450 = 0.803 ± 0.029), pET28a-inaQn-P
(GI.1) (OD450 = 0.759 ± 0.008), and pET28a-inaQn-P (GII.4)
(OD450 = 0.763± 0.005) (p > 0.05). However, absorbance signal
of pET28a-inaQn-ORF2 (GII.4) (OD450 = 0.555 ± 0.012) was
significantly lower than the residual groups (p < 0.01).
Binding of HBGAs with Surface Displayed
VP1 and P Domains
To identify the HBGAs receptor-binding capacity, E. coli BL21
cells were transformed with plasmids pET-28a, pET28a-ORF2
(GI.1), pET28a-inaQn-ORF2 (GI.1), pET28a-P (GI.1), pET28a-
inaQn-P (GI.1), pET28a-ORF2 (GII.4), pET28a-inaQn-ORF2
(GII.4), pET28a-P (GII.4), and pET28a-inaQn-P (GII.4). The
HBGAs binding capacity was evaluated by colony counting
assay. When bacteria transformed with HuNoVs capsid protein
encoding genes were added to PGM coated wells, the binding
capacity between the HBGAs in PGM and displayed VP1 or
FIGURE 2 | HBGAs binding assay. HBGAs binding abilities of E. coli with
recombinant HuNoVs VP1/P domains () expression and recombinant
InaQN-HuNoVs VP1/P domains expression ( ). Bars represent standard error.
P domains was determined by comparing the binding ratio of
CFU in wells with or without PGM (Figure 2). The HBGAs
binding capacity was 10.5± 0.4%, 12.5± 0.3%, 24.0± 0.3%, and
27.3 ± 0.9% in bacteria transformed with pET28a-inaQn-ORF2
(GI.1), pET28a-inaQn-P (GI.1), pET28a-inaQn-ORF2 (GII.4),
and pET28a-inaQn-P (GII.4), respectively. The HBGAs binding
capacity was 5.5 ± 0.4%, 3.3 ± 0.1%, 12.3 ± 0.2%, and 7.4 ±
0.3% in bacteria transformedwith pET28a-ORF2 (GI.1), pET28a-
P (GI.1), pET28a-ORF2 (GII.4), and pET28a-P (GII.4) without
inaQn, respectively. Therefore, the HBGAs binding capacity
of InaQN fused VP1s and P particles was significantly higher
than groups without InaQN (p < 0.01). The HBGAs binding
capacities of displayed P domains from both genotypes are
slightly higher than displayed VP1. However, the HBGAs binding
capacities of both displayed VP1 and P domains of GI.1 were
significantly lower than that of GII.4.
DISCUSSION
In this study, cell surface display systems for HuNoVs capsid
protein VP1 and P domains were constructed using InaQN as
a carrier protein. To our knowledge, it is the first report on
HuNoVs displayed the surface of transformed bacteria. Our
results indicated that displayed VP1 or P domains of HuNoVs
were successfully anchored on the surface of bacterial cells. The
surface displayed VP1 or P domains maintained the antigenicity
(Figure 1). The cell surface display using INP has been used in
vaccine development. For example, a recombinant oral vaccine
for hepatitis C has been tested (Lee et al., 2000). Therefore,
this system could be a good candidate for vaccine development.
Currently, we are in the process of using these cell surface
displayed VP1 and P domains for vaccine candidate for HuNoVs.
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TheHBGAs have been recognized as receptors or co-receptors
for HuNoVs (Huang et al., 2003). In this study, we demonstrated
that the displayed viral proteins could interact with the HBGAs
viral receptors (Figure 2). The HBGAs binding capacity of the
displayed VP1 and P domains from GII.4 were significantly
higher than displayed VP1 and P domains from GI.1, indicating
GII.4 P domains or VP1 may fold more perfectly and be easily
recognized by viral receptors than GI.1 P domains or VP1.
Recently, sialic acids have been identified as additional cellular
receptors/co-receptor for Tulane virus (Tan et al., 2015) and
for HuNoVs (Rydell et al., 2009). It is possible that other
receptors or ligands for HuNoVs have not been identified.
VLP and P particles are limited for valuing in collection or
isolation of HuNoVs receptors or ligands. VLP and P particles
could not be used to get viral particle-ligand complex unless
ultracentrifugation is applied. It is not practical to collect or
isolate a viral particle-ligand complex by ultracentrifugation due
to the small sample size. In this study, the results demonstrated
that the viral capsid protein-receptor complex could be easily
collected by low speed centrifugation. The cell surface display
system we described in this paper could be an alternative method
to replace the ultracentrifugation to collect the viral capsid
binding ligands.
There was some background binding in bacteria expressing
the viral capsid proteins (VP1 and P domains) without the inaQn
gene. The background noise could be a result of non-specific
binding of the viral capsid proteins on bacteria or nonspecific
binding of the antibodies to bacteria as the antibodies were made
from viral capsid proteins, which expressed in E. coli BL21. The
background should be reduced significantly when the targets are
viral receptors or ligands. Currently, we are in the process of
isolating candidate ligands for HuNoVs using this approach.
This new strategy of using cell surface displayed HuNoVs
capsid proteins will provide a new approach to isolate HuNoVs
ligands, a new approach to characterize interaction between
HuNoVs and receptors or ligands, a faster way to construct VP1
or P domains from a new strain or mutated strains. Since a couple
of viral antigens displayed on the bacterial surface using INP
have been proved to be an attractive platform for production of
vaccine (Kim and Yoo, 1999; Kwak et al., 1999; Lee et al., 2000)
and E. coli-expressed norovirus P particle could be a platform for
antibody production (Tan et al., 2011), we believe that cell surface
displayed HuNoVs capsid proteins can also be a good candidate
for vaccine development.
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